Skip to main content
REVELATION BIOSCIENCES, INC. logo

REVELATION BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · REVB ISIN · US7164211028 LEI · 549300UKS15BEXENY615 US Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2025-09-09 Regulatory Filings
Country US United States of America
Listing US REVB

About REVELATION BIOSCIENCES, INC.

https://www.revbiosciences.com/

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic-based therapies for the prevention and treatment of disease. The company's core strategy involves rebalancing inflammation and harnessing the innate immune system to optimize health. Its lead product candidate, Gemini, is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®). Gemini is designed to reprogram the innate immune system to respond to stressors like trauma and infection in an attenuated manner, thereby reducing inflammation-associated damage. The company is evaluating Gemini for various applications, including the prevention of post-surgical infections and acute kidney injury.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 9, 2025. It announces positive clinical results from a clinical study and includes a press release and a corporate presentation as exhibits. The document does not contain detailed financial statements or substantive financial data but rather announces events and provides related materials. The length is 4181 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or annual report.
2025-09-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is Item 2.02, which announces the issuance of a press release with financial results for the quarter ended June 30, 2025. The document itself does not contain the financial results but rather furnishes the press release as an exhibit. The length is 3697 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data itself.
2025-08-08 English
10-Q
Interim / Quarterly Report Q2 2025
2025-08-08 English
8-K
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on a reverse stock split, an amendment to the certificate of incorporation, and related corporate actions. It includes details about the stock split ratio, effective date, and adjustments to equity awards and warrants. There is no detailed financial performance data or comprehensive financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement or voting results announcement. The primary subject is a capital structure change (reverse stock split). According to the filing definitions, announcements about share capital changes such as reverse stock splits fall under Share Issue/Capital Change (SHA). The document is sufficiently detailed and not merely a brief announcement, so it is classified as SHA rather than RPA or RNS.
2025-07-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 23, 2025, for Revelation Biosciences, Inc. It reports the submission of matters to a vote of security holders at the Annual Meeting, including detailed voting results on multiple proposals such as election of director, approval of equity plan amendments, advisory votes on executive compensation, reverse stock splits, issuance of common stock, change of corporate domicile, and ratification of the auditor. The document also includes a brief presentation by the CEO on corporate updates, furnished as an exhibit. The key content is the official results from shareholder votes at the Annual Meeting, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report, proxy statement, or earnings release, but specifically reports voting outcomes. Therefore, the correct classification is DVA with high confidence.
2025-06-25 English
DEF 14A
Proxy Solicitation & Information Statement
2025-06-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.